Genzyme Spinout Peptimmune Takes $41M First Round

Mar 12, 2003

NEW YORK, March 12 -- Peptimmune, a subsidiary company spun out of Genzyme in January 2002, today announced a $41 million first round funding led by New Enterprise Associates and MPM Capital.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Silencing for Preeclampsia

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

Settlement Expected in Duke Case

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

This Week in PNAS

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

Something Different

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.

Main menu